Wnt

Items 51-100 of 104

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. Prodigiosin (Prodigiosine) is a secondary metabolite of Symbiotic bacteria, with anti-fungal and anti-cancer activity.
  2. PORCN inhibitor

    IWP-L6 is a potent inhibitor of Porcupine (Porcn), a membrane-bound O-acyltransferase (MBOAT) (EC50 = 0.5 nM).
  3. Wnt inhibitor

    ETC-159 is a potent and specific inhibitor of Wnt secretion. ETC-159 inhibits beta-catenin reporter activity in a dose-dependent manner with an IC50 of 2.9 nM.
  4. Wnt/beta-catenin inhibitor

    IQ-1 is a cell-permeable tetrahydroisoquinolinylidene compound that modulates Wnt/beta-catenin signaling.
  5. Wnt pathway activator

    WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate; with EC50 of 0.63 uM in TCF-Luciferase assay.
  6. Cardiogenol C is a diaminopyrimidine compound that induces the differentiation of MHC- (myosin heavy chain) positive cardiomyocytes from embryonic stem cells with an EC50 value of 0.1 uM. Cardiogenol C upregulates cardiac markers and induces cardiac functional properties in lineage-committed progenitor cells.
  7. Wnt inhibitor

    CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with IC50 value of 5 nM.
  8. Wnt/beta-catenin inhibitor

    Hexachlorophene is a potent KCNQ1/KCNE1 potassium channel activator with EC50 of 4.61 ?? 1.29 uM; also is an inhibitor of Wnt/beta-catenin signaling.
  9. Wnt/beta-catenin inhibitor

    KYA1797K is a highly potent and selective Wnt/beta-catenin inhibitor with IC50 of 0.75 μM (TOPflash assay).
  10. Wnt/β-catenin agonist

    SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction.
  11. PORCN inhibitor

    IWP-O1 is a porcn inhibitor with an EC50 value of 80 pM in a cultured cell reporter assay of Wnt signaling and effectively suppresses the phosphorylation of Dvl2/3 in HeLa cells.
  12. Wnt/β-catenin antagonist

    iCRT3 is an antagonist of Wnt/β-catenin signaling with an IC50 of 8.2 nM in the Wnt responsive STF16-luc reporter assays.
  13. Porcupine inhibitor

    GNF-6231 is a potent, orally active and selective Porcupine inhibitor with IC50 of 0.8 nM.
  14. LF3

    Wnt inhibitor

    LF3 is a specific inhibitor of canonical Wnt signaling by disrupting the interaction between β-catenin and TCF4 with an IC50 less than 2 μM.
  15. Wnt/β-catenin signaling inhibitor

    IWP-4 is a novel potent inhibitor of Wnt/β-catenin signaling.
  16. TNIK inhibitor

    NCB-0846 is an orally available TNIK inhibitor with an IC50 of 21?nM.
  17. Wnt/β-catenin inhibitor

    PNU-74654 is an inhibitor of Wnt/β-catenin pathway with an IC50 of 129.8 μM in NCI-H295 cell.
  18. Wnt/β-catenin activator

    Methyl vanillate, one of the ingredients in Hovenia dulcis Thunb, is a Wnt/β-catenin pathway activator. A benzoate ester that is the methyl ester of vanillic acid. It has a role as an antioxidant and a plant metabolite.
  19. Prodigiosin (Prodigiosine) HCl is a potent proapoptotic agent, and inhibits Wnt/β-catenin pathway.
  20. Wnt/β-catenin signaling inhibitor

    Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling.
  21. ERbeta agonist

    Prinaberel(ERB-041) is a potent and selective ERbeta agonist; being >200-fold selective for ERbeta.
  22. Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.
  23. Wnt/beta-catenin modulator

    KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway; with an IC50 of 2.1 μM in HEK293 reporter cells.
  24. EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.
  25. Wnt/β-catenin agonist

    Wnt/β-catenin agonist 1 is a Wnt/β-catenin signalling pathway agonist, with an EC50 of 0.27 μM.
  26. FZD4 agonist

    FzM1.8 is an allosteric agonist of the Frizzled receptor FZD4 with pEC50 of 6.4. FzM1.8 binds to FZD4 and activates the WNT/β-catenin pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand. FzM1.8 binding stabilizes FZD4 with an increased affinity for heterotrimeric G protein and stimulates the release of the Gβγ subunit that in turn activates PI3K.
  27. Wnt inhibitor

    Adavivint (SM04690; Lorecivivint) is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.
  28. Wnt/β-catenin signaling inhibitor

    DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC50 of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK.
  29. Salinomycin is an antibacterial and coccidiostat ionophore therapeutic drug.
  30. Wnt inhibitor

    Pyrvinium pamoate is an FDA-approved antihelmintic drug that inhibits WNT pathway signaling.
  31. Potent porcupine inhibitor

    Porcn-IN-1 is potent porcupine inhibitor with an IC50 of 0.5??0.2 nM.
  32. Wnt/β-catenin activator

    HLY78 is an activator of the Wnt/β-catenin signaling pathway, which targets the DIX domain of Axin and potentiates the Axin-LRP6 association to promote Wnt signaling transduction.
  33. WNT Inhibitor

    WNTinib is a selective WNT signaling inhibitor targeting mutated β-catenin (CTNNB1) in hepatocellular carcinoma (HCC). By effectively disrupting the oncogenic Wnt pathway, WNTinib inhibits key kinases such as KIT and MAPK, leading to the reduction of EZH2 activation. This compound is suitable for research applications focused on cancer biology and the mechanisms of liver tumorigenesis.
  34. Wnt/β-catenin Inhibitor

    KWZY-11 is a potent Wnt/β-catenin inhibitor that effectively modulates the associated signaling pathway. This compound demonstrates strong biological activity by inducing DNA damage and promoting apoptosis specifically in MDA-MB-231 breast cancer cells. Its dual inhibition of PARP and CDK6 enhances its potential applications in cancer research, particularly for therapeutic strategies targeting tumor cell proliferation.
  35. Wnt/β-catenin Signaling Activator

    Wnt/β-catenin agonist 2 is a potent activator of the Wnt/β-catenin signaling pathway. This compound effectively stimulates Wnt signaling, making it a valuable tool for investigating the molecular mechanisms underlying diseases associated with aberrant signal transduction. Researchers can utilize this reagent in studies focused on developmental biology, cancer research, and regenerative medicine, where modulation of the Wnt pathway plays a critical role.
  36. Wnt/β-catenin inhibitor

    2,5-Dimethylcelecoxib is a selective Wnt/β-catenin pathway inhibitor that shows promising anticancer activity without inhibiting COX-2. It effectively suppresses cancer cell proliferation by targeting the core elements of this signaling pathway. Additionally, 2,5-Dimethylcelecoxib inhibits T-cell factor-dependent transcriptional activity and downregulates the expression of key Wnt/β-catenin target genes, including cyclin D1 and survivin, making it a valuable tool for cancer research.
  37. wnt/β-catenin Inhibitor

    Teplinovivint is a selective inhibitor of the Wnt/β-catenin signaling pathway. It exhibits significant anti-inflammatory properties and is valuable for research related to tendinopathy and related musculoskeletal disorders. This compound serves as a critical tool for investigating the roles of Wnt signaling in various biological processes and diseases.
  38. Wnt/β-catenin Signaling Activator

    Wnt/β-catenin Agonist 3 is a potent activator of the Wnt/β-catenin signaling pathway. This compound enhances β-catenin-mediated transcriptional activity, making it valuable for research related to bone density disorders such as osteoporosis. Its application in cellular and animal models provides insights into the molecular mechanisms underlying Wnt signaling and offers potential therapeutic avenues for bone-related diseases.
  39. Wnt/β-Catenin Inhibitor

    YW1128 is a potent Wnt/β-Catenin inhibitor that induces the proteasomal degradation of β-catenin, leading to the inhibition of Wnt/β-Catenin signaling pathways in cells. This compound significantly reduces hepatic lipid accumulation and enhances glucose tolerance in mice subjected to a high-fat diet, demonstrating an absence of noticeable toxicity. Furthermore, YW1128 downregulates genes associated with glucose and fatty acid anabolism, making it a valuable tool for research into metabolic disorders and Wnt signaling pathway modulation.
  40. Wnt/β-catenin Signaling Pathway Inhibitor

    Wnt/β-catenin-IN-2 is an inhibitor of the Wnt/β-catenin signaling pathway, displaying an IC50 value of 7.1 μM and a KD value of 2.5 μM. This compound is useful in cancer research, enabling the study of Wnt/β-catenin pathway modulation and its implications in tumorigenesis. Its application can enhance understanding of the mechanistic roles of this pathway in various malignancies.
  41. Wnt/β‐Catenin Activator

    N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide derived from Maca (Lepidium meyenii Walp.) that acts as a Wnt/β-catenin activator. This compound promotes the osteogenic differentiation of mesenchymal stem cells and enhances bone formation by activating the canonical Wnt/β-catenin signaling pathway. It serves as a valuable reagent for research focused on osteoporosis and related conditions.
  42. Wnt Inhibitor

    PTK7/β-catenin-IN-2 is a potent inhibitor of the PTK7/β-catenin interaction, effectively disrupting Wnt/β-catenin signaling with an IC50 of 5.6 μM. This inhibition impairs cell growth mediated by the Wnt pathway and demonstrates potential anticancer activity. Additionally, PTK7/β-catenin-IN-2 exhibits inhibitory effects on the p53-MDM2 interaction, with an IC50 of 157.1 μM, making it valuable for research focused on cancer therapies and signaling pathway modulation.
  43. Wnt/β-catenin Agonist

    SLD1121 is a potent agonist of the Wnt/β-catenin signaling pathway, specifically targeting LRP6 with an inhibition constant (Kd) ranging from 4.52 to 7.49 nM. By interacting with the intracellular domain of LRP6, SLD1121 stabilizes the receptor, enhances its nuclear translocation, and promotes its association with β-catenin, TCF4, or LEF1, leading to the upregulation of Wnt-regulated and stem cell-associated genes. Notably, SLD1121 facilitates the transition of hair follicles from the telogen to anagen phase in the mouse hair growth cycle, making it a valuable reagent for research focused on hair loss and regenerative medicine.
  44. Wnt/β-catenin Signal Inhibitor

    KP-6 is a polypeptide that acts as a Wnt/β-catenin signaling pathway inhibitor. By inhibiting TGF-β, KP-6 disrupts critical fibrotic signaling pathways in vivo, effectively reducing renal tissue damage and fibrotic progression. This compound holds promise for research focused on chronic kidney disease (CKD) and other fibrosis-related disorders, making it a valuable tool for studying disease mechanisms and potential therapeutic interventions.
  45. Wnt/β-catenin Inhibitor

    Wnt/β-catenin-IN-5 is a potent inhibitor of the Wnt/β-catenin signaling pathway. This compound demonstrates significant inhibition of cell proliferation in HCT 116, SW480, and A549 cell lines, with IC50 values of 3.05 μM, 3.27 μM, and 34.91 μM, respectively. It serves as a valuable tool for research focused on cancer biology and the role of Wnt signaling in tumor development and progression.
  46. Wnt/β-catenin Inhibitor

    Wnt/β-catenin-IN-3 is a potent inhibitor of the Wnt/β-catenin signaling pathway, demonstrating low micromolar GI50 values across various cancer cell lines. This compound induces G2/M cell cycle arrest by activating the p53-p21 pathway and promotes apoptotic cell death through both intrinsic and extrinsic mechanisms in colon cancer cells. It serves as a valuable tool for investigating the role of Wnt/β-catenin signaling in cancer biology and therapeutic applications.
  47. Wnt/β-catenin Inhibitor

    Getacatetide is a peptide-based inhibitor of the Wnt/β-catenin signaling pathway. This compound is designed to interfere with the activation of Wnt target genes, making it a valuable tool for investigating the role of Wnt/β-catenin signaling in solid tumors. Getacatetide's ability to disrupt this pathway facilitates research into cancer biology and the development of potential therapeutic strategies.
  48. Wnt Inhibitor

    Halofenate acts as a Wnt inhibitor, impacting the Wnt signaling pathway crucial for cell proliferation and differentiation. It demonstrates significant biological activity by effectively reducing serum triglyceride levels by 50% in hypertriglyceridemic patients and decreasing serum uric acid by 30%, highlighting its potential uricosuric effects. Halofenate additionally increases plasma thyroxine (T4) levels, suggesting implications for thyroid function regulation, supported by in vitro studies showing its ability to displace T4 from thyroid-binding proteins. This compound can be valuable for research into metabolic disorders and thyroid function modulation.
  49. Wnt Inhibitor

    Jatrophone is a diterpenoid that functions as a Wnt inhibitor, exhibiting significant anticancer activity. Isolated from Jatropha isabelli, Jatrophone disrupts the Wnt/β-catenin signaling pathway, leading to a reduction in cell proliferation and inhibition of epithelial-mesenchymal transition (EMT) in triple-negative breast cancer cells. This compound is valuable for research focused on cancer biology and therapeutic strategies targeting Wnt pathway modulation.
  50. Wnt/β-Catenin Inhibitor

    YW2036 is a potent inhibitor of the Wnt/β-Catenin signaling pathway, exhibiting an IC50 value of 637 nM. This compound has significant biological activity and is primarily utilized in research focused on colorectal cancer (CRC). Its role as a Wnt/β-Catenin inhibitor makes it a valuable tool for studies investigating the mechanisms underlying CRC progression and treatment approaches.

Items 51-100 of 104

Page
per page
Set Descending Direction